Market News AIOpen the app

Werewolf Therapeutics (HOWL) shares surge nearly 90% in after-hours trading following a $28 million agreement with EMD Serono.

MarketRead the original at benzinga.com
Neutral

The company surged 90% after hours due to the sale of its pre-clinical technology platforms, providing substantial upfront cash and retaining rights to clinical-stage programs.

HOWL · Werewolf Therapeutics Inc.

AI read · Neutral

The AI's read

Werewolf sold its pre-clinical INDUCER and INDUKINE platforms to EMD Serono and will collect $28 million upfront plus $5 million on transfer. The company kept full rights to its clinical-stage programs and secured an exclusive license. The market already doubled the stock after hours, so most immediate upside looks priced in. The upfront cash exceeds HOWL's market cap and cuts near-term dilution risk. We lean neutral because the deal meaningfully de-risks the balance sheet but the stock has run hard into that news. Let post-spike volatility settle before raising conviction.

MERK · EMD Serono Research & Development Institute Inc.

AI read · Good for MERK

The connection

Acquisition of Werewolf's technology platforms enhances EMD Serono's portfolio and capabilities in immune-stimulating therapies.

Get alerts for HOWL

Follow Werewolf Therapeutics Inc. (HOWL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for HOWL
Free on the App Store and Google Play, or on the web.